Pulmonary resection for multi–drug resistant tuberculosis  by Pomerantz, Benjamin J. et al.
Pulmonary infection with Mycobacterium tuberculosis(MTB) continues to be a major cause of morbidity
and mortality throughout the world. The increase in
MTB infection has prompted the World Health
448
Organization to declare MTB a global emergency.1 In
1995 MTB resulted in more deaths than any other infec-
tious disease.1 Currently, it is estimated that almost one
third of the world’s population is infected with MTB.2
Numerous projects have been implemented throughout
the world in an attempt to slow the spread of MTB. The
result of such projects has been to slow the rate of infec-
tion and improve the cure rate in certain countries.
However, another result of MTB therapy has been the
emergence of multi–drug resistant MTB (MDR-TB). To
be classified as MDR-TB, the tuberculosis bacillus must
be resistant to both isoniazid and rifampin. Emergence
of MTB strains resistant to the primary antibiotics has
largely been due to physician and patient complacency,
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which raises the concern of a new worldwide epidemic
of MDR-TB. When characterized by lung destruction or
persistent cavitary disease, MDR-TB is difficult to treat
with medical therapy alone.
Surgery for pulmonary MTB infection was an
important form of therapy until the introduction of
effective antibiotics in the 1960s. Since that time,
surgery has largely been supplanted by medical ther-
apy. With the emergence of MDR-TB, surgery is
again becoming a necessary treatment modality.
Indications for surgery in patients infected with
MDR-TB include highly resistant MTB with local-
ized disease, persistent cavitary disease, continued
sputum positivity, MDR-TB with destroyed lobe or
lung, massive hemoptysis, bronchopleural fistula,
and bronchial stenosis. We report our series of 172
patients undergoing 180 pulmonary resections for
MDR-TB infection.
Patients and methods
We retrospectively reviewed the hospital records of patients
who underwent pulmonary resection for MDR-TB. Between
August 1983 and April 2000, 172 patients with pulmonary
tuberculosis resistant to isoniazid and rifampin underwent
180 pulmonary resections. All operations were performed by
the senior author (M.P.). In most patients, the infection was
resistant to 6 or more antibiotics. Racial distribution is listed
in Table I. The group comprised 114 male and 66 female
patients and the average age was 39 years.
All patients had received individualized multiple-drug
chemotherapy, as determined by drug susceptibility studies.
Timing of the operation is essential and dictated by the degree
of resistance and the mycobacterial counts. Those patients in
whom the organism is resistant to almost all antibiotics are
usually operated on within 1 to 2 months after initiation of the
best available therapy. Patients in whom the organism is sen-
sitive to some of the primary antibiotics, as well as other
antibiotics, usually have therapy for at least 3 months. By this
time the sputum is either negative for acid-fast organisms or
the mycobacterial count is as low as it will get. It is critical to
operate before the mycobacterial count begins to rise. The
chemotherapy regimen was continued postoperatively for a
maximum of 2 years after conversion of the sputum and cul-
ture to negative. Preoperative evaluation included chest radi-
ography, computed tomography with contrast medium, venti-
lation/perfusion scans, pulmonary function tests,
bronchoscopy, and right heart catheterization when there was
a question of pulmonary hypertension. In addition, all
patients underwent a nutritional evaluation and received
appropriate supplementation.
At the time of the operation, approximately 50% of the
patients had sputum positive for MTB. A total of 170 patients
were operated on for MDR-TB with localized disease usual-
ly complicated by cavity formation (Fig 1) or destroyed lung
(Fig 2). Often bronchopleural fistulas were present preopera-
Table I. MDR-TB racial distribution 
White 67
Asian 42
African American 30
Hispanic 24
Other 17
Total 180
Fig 1. Computed tomographic scan demonstrating left upper
lobe cavity.
Fig 2. Chest radiograph demonstrating total left lung
destruction.
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tively. Only 1 patient was operated on for bronchial stenosis
and only 1 patient had massive hemoptysis, which had
stopped before the operation.
Surgical resection was performed with the patient under
general anesthesia. A double-lumen endobronchial tube or
an endotracheal tube with a bronchial blocker was used. A
combination of single-dose narcotic intrathecal analgesia
(Duramorph; Elkins-Sinn, Inc, Cherry Hill, NJ), epidural
analgesia, patient-controlled analgesia, and rib blocks with
local anesthesia were used for postoperative pain control.
In addition, intravenous ketorolac (Merck & Company,
Whitehouse Station, NJ) has been used for up to 3 days
after surgery. Operations performed are listed in Tables II
and III. After the initial 8 patients, all patients with positive
sputum at the time of the operation underwent placement of
a muscle flap to buttress the bronchial stump. The tech-
nique of muscle flap construction used was initially
described by Pairolero, Arnold, and Piehler.3 The serratus
anterior muscle was initially used, but the latissimus dorsi
muscle is now our muscle of choice. The latissimus dorsi is
dissected from the chest wall, with the vascular supply left
intact. A portion of either the third or fourth rib is resected,
through which the muscle is passed into the thoracic cavi-
ty. The muscle is then placed over the bronchial stump and
secured with suture. A total of 91 muscle flaps were used.
The indications for use of a muscle flap are (1) positive
sputum at the time of surgery, (2) pre-existing bron-
chopleural fistula, (3) polymicrobial contamination of the
thoracic cavity, and (4) anticipated space problems after
lobectomy. Muscle flaps were not used after lower lobec-
tomies or segmental resections. One patient underwent a
completion pneumonectomy with placement of an omental
flap to cover the bronchial stump. The indication for an
omental flap in this patient was a previous thoracotomy
with inadequate viable muscle to cover the bronchial
stump. Eight patients underwent multiple surgical proce-
dures (Table IV). Six of these operations were performed in
a staged fashion and were done 4 to 6 weeks apart. Two
patients who underwent a right upper lobectomy had a
completion pneumonectomy after recurrent disease. The
majority of resections were done extrapleurally because of
obliteration of the pleural space largely due to the involve-
ment of parietal pleura in the cavity wall.
Results
Follow-up was complete in all patients. The aver-
age period of follow-up was 7.7 years (range 4
months–17 years). There were 6 early deaths (30-day
mortality 3.3%). Postpneumonectomy pulmonary
edema, bronchopleural fistula with respiratory fail-
ure, and myocardial infarction each accounted for 1
death. Cerebral vascular accidents accounted for 2
early deaths, 1 of which occurred in a patient who
had had renal transplantation. There were a total of
11 late deaths. Four patients died of late respiratory
failure and 3 patients of recurrent MDR-TB. One
patient each died of a self-induced drug overdose,
myocardial infarction, and renal failure. One death
was due to an unknown cause. Late mortality was
6.8%. Twenty patients had postoperative complica-
tions (Table V). Six patients had respiratory failure
necessitating prolonged ventilator assistance, 5 had a
bronchopleural fistula, all of whom had positive spu-
tum at the time of the operation, and 3 had wound
infections. Three patients required 4 or more units of
packed red blood cells for postoperative bleeding,
and 2 patients had recurrent laryngeal nerve injury.
Intrathoracic bowel herniation occurred in the 1
patient in whom an omental flap was used. This her-
nia was repaired 6 months after the initial operation
without subsequent adverse complications.
Table II. Pneumonectomies performed for MDR-TB
Left Right
Pneumonectomy 15 4
Pneumonectomy + muscle flap 34 12
Pneumonectomy + muscle flap + Eloesser 1 0
Completion pneumonectomy 2 1
Completion pneumonectomy + muscle flap 7 5
Completion pneumonectomy + omentum 1 0
Total 60 22
Table III. Lobectomies performed for MDR-TB
Operation No. 
Right upper lobectomy* 47
Right upper and middle lobectomy† 8
Right lower lobectomy 4
Left upper lobectomy‡ 28
Left lower lobectomy 6
Segmental resections 5
Total 98
*Sixteen lobectomies with muscle flaps.
†Two bilobectomies with muscle flaps.
‡Fourteen lobectomies with muscle flaps.
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Discussion
The incidence of MDR-TB has risen considerably
throughout the world. Largely as a result of the com-
placency of physicians and patients, as well as the
high rate of infection in developing countries, strains
of MTB resistant to conventional antimicrobial
agents have emerged. Tuberculosis, once thought to
be easily controlled, continues to be a major cause of
morbidity and mortality. The World Health
Organization has expressed deep concern that a
worldwide epidemic of MDR-TB appears immi-
nent.2,4,5 Clearly, newer chemotherapeutic agents will
be necessary to combat this increasing incidence of
MDR-TB. However, surgical resection will likely
remain a crucial adjunct to medical therapy in
addressing this epidemic.
The economic impact of tuberculosis is far reaching.
With almost one third of the world’s population (1.3
billion persons) infected with tuberculosis, proper
treatment presents a challenge in developing countries.
Even more discouraging is that in developing countries,
90% of persons infected with tuberculosis are younger
than the age of 50.1 Unfortunately, this group repre-
sents the primary wage earners in these countries. It is
necessary to identify patients early who may benefit
from surgery to limit the economic impact of this dis-
ease. Furthermore, the cost of treating drug-sensitive
tuberculosis may range from $2,000 to $15,000. This
pales in comparison with the treatment of MDR-TB,
which may approach $200,000 (Iseman M: Personal
communication, 2000).
In the 21st century, absolute indications for surgical
treatment of MDR-TB are persistent cavitary disease
and lung or lobar destruction. Currently, MDR-TB and
its associated complications are the primary indications
for pulmonary tuberculosis surgery in the United
States. The reasons for resection in patients with cavi-
tary disease are the difficulty of antibiotic penetration
and the high number of organisms contained within the
cavity, 107 to 109 organisms per cavity.6 For these rea-
sons, it is important to resect all cavitary disease and
destroyed lung, leaving no grossly diseased lung
behind.
The operative mortality in our series is consistent
with that for lobectomies and pneumonectomies for
patients with cancer. This is surprising given that our
cohort of patients underwent more difficult procedures
with a relatively higher incidence of comorbid risk fac-
tors. The low late mortality is due in part to the aggres-
sive medical therapy and prolonged follow-up by our
medical colleagues. In most cases, postoperative
antibiotic therapy is continued for 2 years after conver-
sion of the sputum smear and culture to negative.
Anatomically, this experience reveals several intrigu-
ing observations. Left lung destruction was found in
more than 70% of the patients who underwent a pneu-
monectomy. The predilection for left lung destruction
in patients with pulmonary tuberculosis has been
reported by others.7,8 The reason for this is not clear. It
is possible that the anatomic differences between the
left and right main stem bronchi and the location of the
lobar bronchi may account for this discrepancy. When
there is isolated infection without total lung destruc-
tion, the right upper lobe is the most common site of
infection.
Malnutrition remains a major problem in this group
of patients. All but 2 of the 172 patients were at or
below their ideal body weight. We use aggressive pre-
operative enteral and parenteral supplementation in an
attempt to obtain a positive nitrogen balance and
increase the serum albumin level to 3 g/dL or greater.
These goals are difficult to achieve in a number of
patients because of the severity of their illness.
We were surprised to find that only 3 patients in our
series died of recurrent MDR-TB. We believe this low
Table IV. Multiple operations
First operation Second operation No. 
Right upper lobectomy + muscle Left upper lobectomy + muscle 4
Left pneumonectomy + muscle Right upper lobectomy + muscle 2
Right upper lobectomy Completion pneumonectomy + muscle 2
Total 8
Table V. Complications of MDR-TB 
No.
Respiratory failure 6
Bronchopleural fistula 5
Wound infection 3
Postoperative hemorrhage 3
Recurrent nerve injury 2
Intrathoracic bowel herniation 1
Total 20
mortality is due in large part to the prolonged postop-
erative use of appropriate antibiotics. In addition, opti-
mal timing of surgical intervention remains difficult to
determine. We would advocate that positive sputum be
converted to negative sputum and that pulmonary
mechanics be maximized with aggressive preoperative
pulmonary rehabilitation. The presence of the senior
author (M.P.) in weekly multidisciplinary myocobacte-
rial rounds was essential. A certain number of patients
required intervention before these goals could be
obtained, because their disease was pursuing a virulent,
aggressive course. The combination of surgery along
with the continuation of directly observed antitubercu-
losis therapy is very effective for the treatment of
MDR-TB.
To our knowledge, this is the largest series of patients
operated on for MDR-TB. We have demonstrated that
although patients with MDR-TB are often quite ill,
with little functional reserve, they can be operated on
with a reasonably low operative mortality (3.3%) and
with acceptable morbidity. In our experience, the use of
muscle flaps has decreased the incidence of bronchial
stump dehiscence and residual space problems with lit-
tle associated morbidity. Given the increasing global
epidemic of MDR-TB, it is likely that thoracic sur-
geons in the 21st century will occupy an integral role in
the optimal treatment of MDR-TB. The experience and
judgment of the surgeon, combined with dedicated pul-
monologists, infectious disease physicians, and periop-
erative support, undoubtedly will contribute to the low
morbidity and mortality in this difficult group of
patients.
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Discussion
Dr John R. Benfield (Los Angeles, Calif). My congratula-
tions to Marvin Pomerantz for the outstanding results and to
Ben Pomerantz for a fine report of this largest of all reported
series of patients in whom MDR-TB was treated with opera-
tions that are among the most technically challenging in
surgery. 
John Alexander of the University of Michigan is remem-
bered for his classic book about collapse therapy for the treat-
ment of tuberculosis, a mode of treatment that was ending as
I was entering thoracic surgery. During the subsequent 40
years of my practice, I saw the number of thoracic surgeons
with personal experience in the surgery of tuberculosis dwin-
dle to almost naught. Today’s presentation tells us that MDR-
TB is a persistent and growing problem and that modern tho-
racic surgeons are needed to solve the problem. It is
remarkable that all except 4 of 91 patients, who had positive
sputum at the time of their operations, achieved negative spu-
tum as a result of resections of destroyed lung and oblitera-
tion of pleural space. The basic principles remain unchanged:
best available drug therapy, followed by resection of residual
active foci of disease, accompanied by obliteration of abnor-
mal pleural spaces, followed by best available drug therapy. 
Even the best results demand analysis with the question of
whether and how one might have done better. Therefore, I
wish to focus on the 11 patients (6.8%) who died in the late
postoperative period and the 3 patients who died of respirato-
ry failure during the postoperative period. Retrospectively,
could anything have been done to avoid these deaths? Were at
least some of these patients sufficiently dysfunctional preop-
eratively to justify resurrection of collapse therapy such as a
thoracoplasty or a muscle flap without pulmonary resection?
In my own experience of treating patients with far-advanced
MDR-TB, often from Southeast Asia or the former Soviet
Union, at intervals of 12 to 24 months I would encounter a
patient for whom a modern version of collapse therapy was
the best available treatment. What has been the experience of
the National Jewish Hospital/University of Colorado group
with collapse therapy in recent years?
Dr Pomerantz. We have not used collapse therapy at all
for the treatment of tuberculosis, but we do use it for the treat-
ment of other pulmonary diseases. With the excellent results
we achieve with primary resection and the association of pro-
gressive respiratory failure with thoracoplasty, we believe
that we have better results doing a primary resection. Just to
touch on the 3 late respiratory deaths, pulmonary hyperten-
sion developed in 1 of those patients after lobectomy, and we
452 Pomerantz et al The Journal of Thoracic and
Cardiovascular Surgery
March 2001
technical problems other than the usual problems associated
with an extrapleural dissection in that 1 patient. 
Dr Mark. I remember in the old days when we were doing
these types of operations, we used to yearn for a nice clean
cancer case.
Dr Pomerantz. That is right.
Dr Steven Guyton (Seattle, Wash). Dr Pomerantz, you had
5 bronchopleural fistulas. Did they occur in the presence of a
muscle flap, or were they lower lobe fistulas?
Dr Pomerantz. I believe all of them were without muscle
flaps and were in patients with positive sputum. I do not
remember the specifics, but more than half of our patients did
get muscle flaps.
Dr Arthur Thomas (San Francisco, Calif). I congratulate
you for a very important paper on the largest series of patients
of this type, comprising more patients than any of the rest of
us have seen. I would like to hear a little detail about your
technique of closing bronchial stumps. Are these stapled? Are
they hand sewn? If they are hand sewn, what suture material
did you use? 
Dr Pomerantz. We generally use a staple closure for the
bronchial stump. If the bronchial stump is too short, we sew
it closed by hand, usually with Prolene sutures.
Dr Quentin Stiles (Palos Verdes Estates, Calif). Dr
Pomerantz, your paper reminds me of the old days, and I am
talking about the really old days, even before the formation of
the Samson Thoracic Surgical Association. The point that
really struck me was your statement that 2 billion persons are
affected by tuberculosis. You must be talking about people
with positive skin tests. Two billion is one third of the popu-
lation of the whole universe.
Dr Pomerantz. Yes, that is right. Those are the individuals
who test positive for purified protein derivative, and about
10% of them actually harbor the active infectious disease.
There are more than 3 million deaths annually from tubercu-
losis. It is estimated that 100,000 persons in Russia have
MDR-TB. This disease is a huge global problem. A primary
reason for the problem is the global economic issues in devel-
oping countries, which seem to be the predominant harborers
of this disease.
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are not exactly sure why. The other 2 patients had pneu-
monectomy on one side and old tuberculosis on the opposite
side, which had caused a lot of scarring, and they had pro-
gressive pulmonary fibrosis.
Dr Benfield. This report clearly supports the liberal pro-
phylactic use of muscle flaps to cover bronchial closure
sites and to obliterate pleural spaces. I cannot recall a sin-
gle occasion of regret that I had used a muscle flap, and
each of us can remember times when we wished we had
used one. In the manuscript I noted that muscle flaps were
routinely used to cover upper lobe and main stem bronchial
closures, but they were not routinely used after lower
lobectomies. Of course, this is because of the expectation
that the diaphragm can rise and that space problems are less
frequent after lower lobectomies than after upper lobe
resections. Nonetheless, I suspect that there were instances
of using muscle flaps or some modification of collapse
therapy in conjunction with lower lobectomies. Would you
please comment about this point? 
Dr Pomerantz. We performed only 10 lower lobectomies.
We did not encounter any space problems in these patients.
We did, however, try to cover the bronchial stump with either
pleura or a pericardial fat pad.
Dr James B. D. Mark (Stanford, Calif). I would like to
congratulate Dr Pomerantz the elder for his persistent work in
treating this difficult disease over an extended period and Dr
Pomerantz the younger for a very fine presentation. Those of
you in this room who have not had experience with this oper-
ation, and I suspect that represents the great majority, have no
idea about the technical problems that one may face or the
blood, sweat, and tears involved in taking care of these
patients in the operating room. The greatest challenge in this
group, I think, is operating under a thoracoplasty. You men-
tioned that you did not do any collapse procedures, but were
you faced with operating under a previous thoracoplasty?
Would you comment on any special technical problems that
you encountered? 
Dr Pomerantz. One patient did have a previous thora-
coplasty, and the extrapleural dissection was challenging
enough by itself. We did not really encounter any specific
